NCT04338659View on ClinicalTrials.gov

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Advanced Malignant Tumors Lymphomas
Interventions
BIOLOGICAL

IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection

IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Trial Locations (4)

39313

University Of Mississippi Medical Center, Jackson

66205

The University of Kansas Cancer Center, Westwood

77030

The University of Texas MD Anderson Cancer Center - Investigational Cancer Therapies, Houston

90025

The Angeles Clinic And Research Institute, Los Angeles

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04338659 - A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers | Biotech Hunter | Biotech Hunter